Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (151-160 of 361) with videos related to

Pageof 37
Sort By:
Clinical Genitourinary Cancer|July 25, 2007
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancerAmy M Lin, Brian I Rini, Mika K Derynck, et al.
Molecular Imaging and Biology|May 18, 2016
A Feasibility Study Showing [<sup>68</sup>Ga]Citrate PET Detects Prostate CancerSpencer C Behr, Rahul Aggarwal, Youngho Seo, et al.
Contemporary Clinical Trials Communications|December 25, 2019
How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trialsHala T Borno, Eric J Small, Li Zhang, et al.
Urology|February 23, 2008
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)Anthony V D'Amico, Susan Halabi, Robin Vollmer, et al.
Journal of Cancer Policy|May 13, 2022
Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysisHala T Borno, Tracy Kuo Lin, Sylvia Zhang, et al.
Cancer|March 10, 2011
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinomaAndrea L Harzstark, Eric J Small, Vivian K Weinberg, et al.
Cancer|December 20, 2011
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782J Paul Monk, Susan Halabi, Joel Picus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trialCharles J Ryan, Arturo Molina, Jinhui Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 24, 2016
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human ExperienceThomas A Hope, Charles Truillet, Eric C Ehman, et al.
Cancer Immunology Research|May 14, 2015
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with IpilimumabSerena S Kwek, Jera Lewis, Li Zhang, et al.
Pageof 37

Showing results (151-160 of 361) with videos related to

Sort By:
Pageof 37
Clinical Genitourinary Cancer|July 25, 2007
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancerAmy M Lin, Brian I Rini, Mika K Derynck, et al.
Molecular Imaging and Biology|May 18, 2016
A Feasibility Study Showing [<sup>68</sup>Ga]Citrate PET Detects Prostate CancerSpencer C Behr, Rahul Aggarwal, Youngho Seo, et al.
Contemporary Clinical Trials Communications|December 25, 2019
How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trialsHala T Borno, Eric J Small, Li Zhang, et al.
Urology|February 23, 2008
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)Anthony V D'Amico, Susan Halabi, Robin Vollmer, et al.
Journal of Cancer Policy|May 13, 2022
Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysisHala T Borno, Tracy Kuo Lin, Sylvia Zhang, et al.
Cancer|March 10, 2011
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinomaAndrea L Harzstark, Eric J Small, Vivian K Weinberg, et al.
Cancer|December 20, 2011
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782J Paul Monk, Susan Halabi, Joel Picus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trialCharles J Ryan, Arturo Molina, Jinhui Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 24, 2016
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human ExperienceThomas A Hope, Charles Truillet, Eric C Ehman, et al.
Cancer Immunology Research|May 14, 2015
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with IpilimumabSerena S Kwek, Jera Lewis, Li Zhang, et al.
Pageof 37